By Definitive Healthcare, a healthcare commercial intelligence company based in Framingham, Mass., experienced a decline in its stock value after the removal of its chief executive officer (CEO). The shares of the company fell by 8.9% to $8.37 during Wednesday morning trading, contributing to a total decrease of 28% over the course of the past 12 months.
On Tuesday, after the market closed, Definitive Healthcare announced that Robert Musslewhite had resigned as CEO and from the board of directors. According to a filing with the Securities & Exchange Commission, this departure was classified as a “termination of employment without cause.”
In response to Musslewhite’s departure, the company appointed Jason Krantz, its founder and former CEO, as the interim leader effectively starting from January 16.
Despite this setback, Definitive Healthcare remains confident in its financial performance for the full year of 2024. The company has stated that it expects its revenue to grow by 5% to 7% from its fiscal 2023 revenue of $222.7 million. Analysts, however, predict a slightly higher revenue of $251.5 million for the year 2024, according to a poll conducted by FactSet.
It is evident that Definitive Healthcare is facing a period of transition and uncertainty following the departure of its CEO. The company’s ability to navigate these challenges and meet their revenue targets will be closely monitored by industry observers.
Comments